These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29053231)

  • 21. Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels.
    Blauw H; Wendl I; DeVries JH; Heise T; Jax T;
    Diabetes Obes Metab; 2016 Jan; 18(1):34-9. PubMed ID: 26343550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and glucodynamic comparisons of recombinant and animal-source glucagon after IV, IM, and SC injection in healthy volunteers.
    Graf CJ; Woodworth JR; Seger ME; Holcombe JH; Bowsher RR; Lynch R
    J Pharm Sci; 1999 Oct; 88(10):991-5. PubMed ID: 10514345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
    Hövelmann U; Olsen MB; Mouritzen U; Lamers D; Kronshage B; Heise T
    Diabetes Obes Metab; 2019 Mar; 21(3):601-610. PubMed ID: 30350477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nasal airflow asymmetry and the effects of a topical nasal decongestant.
    Williams RG; Eccles R
    Rhinology; 1992 Dec; 30(4):277-82. PubMed ID: 1281924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nasal decongestants for the common cold.
    Taverner D; Latte J
    Cochrane Database Syst Rev; 2007 Jan; (1):CD001953. PubMed ID: 17253470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus.
    Stenninger E; Aman J
    Diabetologia; 1993 Oct; 36(10):931-5. PubMed ID: 8243872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality?
    Pontiroli AE; Ceriani V
    Diabetes Obes Metab; 2018 Aug; 20(8):1812-1816. PubMed ID: 29652110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment.
    Zannikos P; Solanki B; De Meulder M; Badorrek P; Hohlfeld JM; Singh J
    Clin Pharmacokinet; 2023 Sep; 62(9):1315-1328. PubMed ID: 37402024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WITHDRAWN: Nasal decongestants for the common cold.
    Taverner D; Latte GJ
    Cochrane Database Syst Rev; 2009 Apr; 2009(2):CD001953. PubMed ID: 19370573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral antihistamine-decongestant-analgesic combinations for the common cold.
    De Sutter AI; van Driel ML; Kumar AA; Lesslar O; Skrt A
    Cochrane Database Syst Rev; 2012 Feb; (2):CD004976. PubMed ID: 22336807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nasal decongestants for the common cold.
    Taverner D; Bickford L; Draper M
    Cochrane Database Syst Rev; 2000; (2):CD001953. PubMed ID: 10796673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucose recovery after intranasal glucagon during hypoglycaemia in man.
    Hvidberg A; Djurup R; Hilsted J
    Eur J Clin Pharmacol; 1994; 46(1):15-7. PubMed ID: 7911762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of intranasal ipratropium bromide in common colds. A randomized, double-blind, placebo-controlled trial.
    Hayden FG; Diamond L; Wood PB; Korts DC; Wecker MT
    Ann Intern Med; 1996 Jul; 125(2):89-97. PubMed ID: 8678385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nasal decongestants for the common cold.
    Taverner D; Latte J; Draper M
    Cochrane Database Syst Rev; 2004; (3):CD001953. PubMed ID: 15266459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal topical local anesthetic and decongestant for flexible nasendoscopy in children: a randomized, double-blind, placebo-controlled trial.
    Chadha NK; Lam GO; Ludemann JP; Kozak FK
    JAMA Otolaryngol Head Neck Surg; 2013 Dec; 139(12):1301-5. PubMed ID: 24158493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.
    Pöhlmann J; Mitchell BD; Bajpai S; Osumili B; Valentine WJ
    J Diabetes Sci Technol; 2019 Sep; 13(5):910-918. PubMed ID: 30700165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [An open label multi-center clinical trial to evaluate the efficacy of compound pseudoephedrine [corrected] hydrochloride sustained release capsules in patients with nasal symptoms associated with common cold].
    New Contac Multi-Center Clinical Cooperative Group ; Xiao Z
    Zhonghua Nei Ke Za Zhi; 2002 Aug; 41(8):547-9. PubMed ID: 12421505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
    Hövelmann U; Bysted BV; Mouritzen U; Macchi F; Lamers D; Kronshage B; Møller DV; Heise T
    Diabetes Care; 2018 Mar; 41(3):531-537. PubMed ID: 29273578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nasal glucagon in the treatment of hypoglycaemia in type 1 (insulin-dependent) diabetic patients.
    Rosenfalck AM; Bendtson I; Jørgensen S; Binder C
    Diabetes Res Clin Pract; 1992 Jul; 17(1):43-50. PubMed ID: 1511660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.
    Portron A; Jadidi S; Sarkar N; DiMarchi R; Schmitt C
    Diabetes Obes Metab; 2017 Oct; 19(10):1446-1453. PubMed ID: 28741871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.